Skip to main content
logo
Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
24.98
+0.92 (3.82%)
Oct 8, 2025, 2:43 PM EDT - Market open

Revenue by Product

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Biopharmaceutical and Diagnostic Solutions
933.74M
Log In
Log In
Log In
Log In
Upgrade
Biopharmaceutical and Diagnostic Solutions Growth
8.50%
Log In
Log In
Log In
Log In
Upgrade
Engineering
170.29M
Log In
Log In
Log In
Log In
Upgrade
Engineering Growth
-10.21%
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Other
6.45M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-12.98%
Log In
Log In
Log In
Log In
Upgrade
Biopharmaceutical and Diagnostic Solutions Operating Profit
165.64M
Log In
Log In
Log In
Log In
Upgrade
Biopharmaceutical and Diagnostic Solutions Operating Profit Growth
14.69%
Log In
Log In
Log In
Log In
Upgrade
Engineering Operating Profit
33.10M
Log In
Log In
Log In
Log In
Upgrade
Engineering Operating Profit Growth
-10.51%
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Operating Profit
-37.59M
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Operating Profit Growth
18.18%
Log In
Log In
Log In
Log In
Upgrade
Other
6.45M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-12.98%
Log In
Log In
Log In
Log In
Upgrade
Other
6.45M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-12.98%
Log In
Log In
Log In
Log In
Upgrade

Gross Income by Product

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Other
3.12M
Log In
Log In
Log In
Log In
Upgrade
Other
3.12M
Log In
Log In
Log In
Log In
Upgrade
Biopharmaceutical and Diagnostic Solutions Gross Profit
268.78M
Log In
Log In
Log In
Log In
Upgrade
Biopharmaceutical and Diagnostic Solutions Gross Profit Growth
23.51%
Log In
Log In
Log In
Log In
Upgrade
Engineering Gross Profit
56.17M
Log In
Log In
Log In
Log In
Upgrade
Engineering Gross Profit Growth
-48.85%
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Gross Profit
-22.63M
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Gross Profit Growth
-24.40%
Log In
Log In
Log In
Log In
Upgrade
Other
3.12M
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
EMEA
667.83M
Log In
Log In
Log In
Log In
Upgrade
EMEA Growth
-
Log In
Log In
Log In
Log In
Upgrade
APAC
96.24M
Log In
Log In
Log In
Log In
Upgrade
APAC Growth
-
Log In
Log In
Log In
Log In
Upgrade
North America
308.95M
Log In
Log In
Log In
Log In
Upgrade
North America Growth
-
Log In
Log In
Log In
Log In
Upgrade
South America
31.02M
Log In
Log In
Log In
Log In
Upgrade
South America Growth
-
Log In
Log In
Log In
Log In
Upgrade

Other

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Backlog
853.00M
Log In
Log In
Log In
Log In
Upgrade
Backlog Growth
-
Log In
Log In
Log In
Log In
Upgrade